Kolon TissueGene Doses First Patient in US Phase III Clinical Trial
On November 21, 2018, BioLife’s customer Kolon TissueGene, Inc., a leader in advanced cell and gene therapies, announced that it has dosed its first patient in its pivotal US Phase III clinical trials for Invossa, a cell and gene therapy in development for knee osteoarthritis (OA). “This is an exciting step for Kolon TissueGene as we…
Read More